HomeAI · summaries
Storia in 3 fonti
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient…
- ·
thehindubusinessline.com
Dr Reddy's delays semaglutide supply due to active ingredient issue
Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.
- ·
thehindu.com
Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit
Dr. Reddy’s delays semaglutide supplies over quality issues, causing shares to drop amid ongoing investigations and commitment to product safety.
- ·
Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit
Dr. Reddy’s delays semaglutide supplies over quality issues, causing shares to drop amid ongoing investigations and commitment to product safety.
- ·
Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue involving the active pharmaceutical…
- ·
Dr Reddy's delays Semaglutide supplies after API-related quality issue
Dr Reddy's delayed Semaglutide supplies after certain batches failed quality specifications due to an API issue. The company said patient safety is unaffected.
- ·
DRL’s semaglutide supply hits a stumbling block, affects other companies too
Generic supplies of semaglutide from Dr Reddy’s Laboratories have hit a stumbling block, and this is having a domino effect across other companies, including Torrent…
- ·
Dr. Reddy’s halts semaglutide supplies on quality concerns, shares plunge, Torrent recalls product
No impact on patient safety or on the product’s existing global regulatory filings
- ·
Dr Reddy’s pauses weight loss drug on quality fears
Dr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the active pharmaceutical ingredient…
- ·
Dr Reddy's extends slide as semaglutide setback threatens first-mover edge
Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could allow competitors to gain ground, weaken…
- ·
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages…